Category Archives: Psoriasis

Editor's Choice Main Category: Eczema / Psoriasis Also Included In: Hypertension Article Date: 11 Apr 2013 - 0:00 PDT

Current ratings for: Psoriasis Increases Risk Of High Blood Pressure

4.5 (2 votes)

Psoriasis is a critical, inflammatory, noncommunicable disease that affects over 125 million people internationally. People with psoriasis are known to have an elevated risk of developing grave co-morbid conditions, such as:

Lars Ettarp, President of IFPA, commented:

There are studies indicating that treating psoriasis early and efficiently lowers the risk for co-morbid conditions, such as high blood pressure, and this needs to be taken into account when developing a treatment regimen for an individual with psoriasis."

This year's World Health Day aimed to highlight the global health crisis of high blood pressure and how it can be avoided, treated, and controlled. Issues associated with high blood pressure cause over 9 million deaths annually around the world and affect more than one in three adults, according to the WHO.

High blood pressure is also linked to several behavioral risk factors, including:

A separate study from 2009, conducted by the Brigham and Women's Hospital, Harvard Medical School and Harvard School of Public Health, in Boston, suggested that psoriasis is associated with an increased risk of diabetes and high blood pressure in women. They said more studies need to be carried out to determine whether treating psoriasis might also reduce the risk of diabetes and hypertension.

In other research released last year, psoriasis patients were encouraged to be aware of their condition and its link to other serious illnesses. These patients are at an increased risk for insulin resistance, obesity, cardiovascular diseases, and abnormal levels of cholesterol.

Read more here:
Psoriasis Increases Risk Of High Blood Pressure

How I cured my psoriasis (part 2)
http://highonhealth.org This video from Ally explores more about her struggle and solution with psoriasis. She has gone through such a deep journey with it.....

By: highonhealth

See the original post:
How I cured my psoriasis (part 2) - Video

WASHINGTON--(BUSINESS WIRE)--

The International Federation of Psoriasis Associations, IFPA, commends the World Health Organization for raising awareness of the risks associated with high blood pressure and calls for healthcare professionals to regularly scan for the condition in patients with psoriasis.

Psoriasis is a serious, inflammatory, noncommunicable disease, affecting more than 125 million people all over the world. People with psoriasis are known to carry an increased risk of developing severe co-morbid conditions such as diabetes and psoriatic arthritis, as well as depression and even suicidal ideation[i]. A number of studies also show that psoriasis is associated with greater prevalence of hypertension[ii], one of the most important risk factors for cardiovascular disease[iii].

Healthcare professionals need to recognize the elevated risk that people with psoriasis carry for developing high blood pressure, and include regular tests for hypertension and other known risk factors of cardiovascular disease for this patient group, says Lars Ettarp, President of IFPA. There are studies indicating that treating psoriasis early and efficiently lowers the risk for co-morbid conditions, such as high blood pressure, and this needs to be taken into account when developing a treatment regimen for an individual with psoriasis.

This years World Health Day focused on the global health crisis of high blood pressure and how it can be prevented, treated and controlled. According to the WHO, complications of high blood pressure account for more than 9 million deaths worldwide per year and affects more than one in three adults[iv]. High blood pressure has been connected to a number of behavioral risk factors, such as high salt intake, excessive use of alcohol and physical inactivity.[v]

However, it must also be acknowledged that there are other markers for hypertension and cardiovascular disease, namely genetic conditions and inflammatory diseases such as psoriasis; conditions that cannot be prevented, but in most cases can, and need to, be treated in order to minimize the risks of further complications.

The International Federation of Psoriasis Associations (IFPA)

The International Federation of Psoriasis Associations (IFPA) is the non-profit umbrella organization for the majority of psoriasis associations from around the world. Today IFPA has 51 member associations covering all regions of the world. IFPA unites psoriasis associations so that their global campaign for improved medical care, greater public understanding and increased research will improve the lives of the more than 125 million people who live with psoriasis and/or psoriatic arthritis. IFPA is actively campaigning for recognition of psoriasis as a serious, noncommunicable disease by the World Health Organizations member states.

You can read more about IFPA, our members and our activities on our website http://www.ifpa-pso.org.

----------------------------------------------------------------------

Read more:
International Federation of Psoriasis Associations: People with Psoriasis have Increased Risk of High Blood Pressure

Targeting psoriasis, rheumatoid arthritis, and other immune diseases has created some massive markets over the last decade. How massive? The market was sized up at an estimated $72.2 billion in 2010, according to BCC Research -- and growth isn't slowing any time soon. That's good news for patients, too. The pharmaceutical industry's fascination with an improved understanding of biologics has led to dozens of drugs that treat the underlying causes of diseases, rather than small molecules of years past that only treated symptoms.

Few companies haven't joined the rush to develop biologics and novel small molecule classes to treat immune diseases. While some companies got a big head start over the field, next-generation therapies are being developed in pipelines across the industry. Merck (NYSE: MRK) is one company looking to capitalize on the trend and will shortly begin phase 3 trials on its leading psoriasis biologic therapy candidate. Going by the catchy pipeline name of MK-3222, the drug has huge potential if it ever receives approval from the Food and Drug Administration, or FDA.

About that competition I mentioned...Older therapies aren't exactly losing their grasp on the markets they took by storm just yet. A quick look at 2012 sales data from the first three biologics approved that work by inhibiting the TNF-alpha protein -- integral to immune system communication -- shows exactly that.

Company

Drug

2012 Sales

Johnson & Johnson (NYSE: JNJ)

Remicade

$6,139 million

Amgen (NASDAQ: AMGN)

Read this article:
Can Merck Field a Psoriasis Blockbuster?

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/svtpzt/severe_psoriasis) has announced the addition of the "Severe Psoriasis - Pipeline Review, H1 2013" report to their offering.

Global Markets Direct's, 'Severe Psoriasis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Severe Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Severe Psoriasis.

Scope

- A snapshot of the global therapeutic scenario for Severe Psoriasis.

- A review of the Severe Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Severe Psoriasis pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

Read the original here:
Research and Markets: Severe Psoriasis - Pipeline Review, H1 2013

On Sunday, April 7, the National Psoriasis Foundation is hosting its annual Walk to Cure Psoriasis at the Aventura Mall (19501 Biscayne Blvd.). The event aims to raise funds for the Foundations research, education and advocacy programs.

Nationwide, as many as 7.5 million people are affected by the disease. Psoriasis, a noncontagious, chronic disease of the immune system, appears on the skin causing red, scaly patches. These patches, often painful and itchy, can appear on any part of the body. Additionally, up to 30 percent of people with psoriasis develop psoriatic arthritis. People with psoriasis are at risk of developing other serious conditions such as heart disease, diabetes and depression.

When: Sunday, April 7, 2013

Registration begins at 7 a.m., walk begins at 8 a.m.

Where: Aventura Mall19501 Biscayne Blvd.

Aventura, FL 33180

Cost: $25 registration fee. All participants will receive a t-shirt.

Choose between 1K and 5K routes on this walk to raise awareness and funds to combat psoriasis and psoriatic arthritis. All ages welcome.

To register or for more information, visit walk.psoriasis.org/sofla-walk, or call 877.825.WALK (9255).

Original post:
Walk to Cure Psoriasis

DUBLIN--(BUSINESS WIRE)--

Research and Markets (http://www.researchandmarkets.com/research/8rr8vz/psoriasis) has announced the addition of the "Psoriasis - Pipeline Review, H1 2013" report to their offering.

This report provides information on the therapeutic development for Psoriasis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Psoriasis.

Psoriasis - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope

- A snapshot of the global therapeutic scenario for Psoriasis.

- A review of the Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Psoriasis pipeline on the basis of route of administration and molecule type.

Read the original here:
Research and Markets: Psoriasis - Pipeline Review, H1 2013

Newswise A dermatology researcher at Case Western Reserve University School of Medicine has secured a five-year, $1.9 million federal grant to explore whether a specific molecule may play a pivotal role in the development and progression of psoriasis.

Nicole Ward, PhD, assistant professor of dermatology, is investigating whether interleukin-17C (IL-17C), a protein key to the regulation of the immune system, may also play a role in the onset and escalation of psoriasis, a chronic, debilitating skin disease that affects an estimated 7.5 million Americans.

The award, from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health, is the second Research Project Grant (R01) Ward has received in the last eight months. This grant will allow her to build upon earlier research suggesting a relationship between IL-17C and another protein (called TNF-alpha) in the emergence of psoriasis.

Psoriasis, an inflammatory autoimmune disease, is characterized by raised areas of red, scaly, itchy and sometimes painful patches of skin. Earlier this year, Ward and colleagues published an article in the Journal of Immunology that reported that psoriasis patients have elevated levels of IL-17C in their skin. Following treatment with TNF-alpha inhibitors, a standard therapy, IL-17C levels drop rapidly, even before the skin visibly improves. This development suggests that the presence, or interaction, of IL17-C and TNF-alpha are critical for the pathogenesis of the disease.

Ward and her colleagues also found that mice genetically engineered to overproduce IL-17C in the skin develop spontaneous lesions that resemble human psoriasis, suggesting a potential critical role for this molecule in disease initiation.. She now hopes to identify how IL-17C synergizes with other inflammatory molecules to cause diseasean understanding that may help identify a new target for drug development.

Although psoriasis is among the most common autoimmune diseases in the country, its cause remains unknown. While treatments to alleviate the condition exist, psoriasis has no cure. Patients are also more likely to be diagnosed with inflammatory bowel disease, cardiovascular disease, and depression. Even more troubling, psoriasis patients generally die seven to 10 years earlier than those without the disease.

Research funded by the NIAMS grant will be directed by Ward with collaborators and co-authors of the Journal of Immunology paper, Thomas McCormick, PhD, of Case Western Reserve, and Johann Gudjonsson, MD, PhD, and Andrew Johnston, PhD, of the University of Michigan.

In addition to the NIAMS grant, Wards research is supported by the National Psoriasis Foundation, the Murdough Family Center for Psoriasis and additional grants from the National Institutes of Health.

###

About Case Western Reserve University School of Medicine Founded in 1843, Case Western Reserve University School of Medicine is the largest medical research institution in Ohio and is among the nations top medical schools for research funding from the National Institutes of Health. The School of Medicine is recognized throughout the international medical community for outstanding achievements in teaching. The Schools innovative and pioneering Western Reserve2 curriculum interweaves four themes--research and scholarship, clinical mastery, leadership, and civic professionalism--to prepare students for the practice of evidence-based medicine in the rapidly changing health care environment of the 21st century. Nine Nobel Laureates have been affiliated with the School of Medicine.

Read more:
Case Western Reserve Awarded $1.9M Grant for Psoriasis Research

Psoriasis Free For Life is a newly updated treatment developed by Katy Wilson, who promises to give home remedies for psoriasis that can help sufferers treat psoriasis quickly and permanently. A full review on the site V-kool shows if the program is helpful for sufferers to use.

Seattle, Wa (PRWEB) April 01, 2013

A full review of Psoriasis Free For Life on the site V-kool points out that this is an effective and safe treatment method that can help sufferers get rid of psoriasis permanently. This new treatment method provides users with helpful tips, which can help them combat the skin problem quickly. This new guide offers three parts such as Diet Cleanse, Detoxifying and Secret Remedies that viewers should follow to achieve their goals in treating psoriasis. These parts give sufferers some detailed explanations about healthy foods they should eat in order to banish psoriasis effectively. In addition, the program supplies sufferers with lots of natural psoriasis treatments in PDF format, which are easy for them to understand and apply. This program also enables viewers to strengthen their immune system response, which can help them heal psoriasis permanently. Additionally, the new method gives up-to-date recipes with the goal of preparing some natural ointments, which will assist sufferers in the psoriasis treating process. The new method also helps viewers decrease the itchiness of pain quickly. In fact, this is an effective and helpful method that can help users banish their psoriasis problem forever, and they do not have to worry about getting it back again.

Kathryn Stone from the site Vkool.com says that: Psoriasis Free For Life is a new treatment that provides users with helpful home remedies for psoriasis, which can teach them how to treat psoriasis permanently. The new program provides users with lots of step-by-step guides that enable them to understand and follow it quickly. In other words, the new method will give a 24/7 supportive service whenever users need.

If people wish to view pros and cons from Psoriasis Free For Life, they could visit the website: http://vkool.com/treatment-for-psoriasis-psoriasis-free-for-life/

For those who desire to achieve instant access to view Psoriasis Free For Life review should visit the official site.

______________

About the website: V-kool is the site built by Tony Nguyen. The site supplies people with tips, ways, programs, methods and e-books about many topics including business, health, entertainment, and lifestyle. People could send their feedback to Tony Nguyen on any digital products via email.

Tony Nguyen V-kool 84915555999 Email Information

See more here:
Home Remedies For Psoriasis | How “ Psoriasis Free For Life” Helps People Treat Psoriasis Quickly – V-kool

Psoriasis Lotion Just Natural Skincare Review - For Dry Flaky Skin
Get it here: http://bit.ly/psoriasislotion Psoriasis isn #39;t acne, but psoriasis is often a skin condition that can go hand in hand with acne and dry skin. Thi...

By: acneerasingsecrets

See the rest here:
Psoriasis Lotion Just Natural Skincare Review - For Dry Flaky Skin - Video